WO2010118243A3 - Use of il-27 antagonists to treat lupus - Google Patents

Use of il-27 antagonists to treat lupus Download PDF

Info

Publication number
WO2010118243A3
WO2010118243A3 PCT/US2010/030412 US2010030412W WO2010118243A3 WO 2010118243 A3 WO2010118243 A3 WO 2010118243A3 US 2010030412 W US2010030412 W US 2010030412W WO 2010118243 A3 WO2010118243 A3 WO 2010118243A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonists
treat lupus
lupus
methods
relates
Prior art date
Application number
PCT/US2010/030412
Other languages
French (fr)
Other versions
WO2010118243A2 (en
Inventor
Nico P. Ghilardi
Marcel L. Batten
Jason A. Hackney
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of WO2010118243A2 publication Critical patent/WO2010118243A2/en
Publication of WO2010118243A3 publication Critical patent/WO2010118243A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

This invention relates to methods of treating the autoimmune disorder lupus with IL- 27 antagonists, as well as articles of manufacture comprising IL- 27 antagonists. The invention also relates to methods and kits for identifying patients that are likely to respond to an IL-27 antagonist treatment.
PCT/US2010/030412 2009-04-08 2010-04-08 Use of il-27 antagonists to treat lupus WO2010118243A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16779309P 2009-04-08 2009-04-08
US61/167,793 2009-04-08
US26718509P 2009-12-07 2009-12-07
US61/267,185 2009-12-07

Publications (2)

Publication Number Publication Date
WO2010118243A2 WO2010118243A2 (en) 2010-10-14
WO2010118243A3 true WO2010118243A3 (en) 2011-01-20

Family

ID=42358325

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/030412 WO2010118243A2 (en) 2009-04-08 2010-04-08 Use of il-27 antagonists to treat lupus

Country Status (2)

Country Link
US (1) US20100297127A1 (en)
WO (1) WO2010118243A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2760774A1 (en) * 2009-05-05 2010-11-11 Altermune Technologies, Llc Chemically programmable immunity
US8741591B2 (en) 2009-10-09 2014-06-03 The Research Foundation For The State University Of New York pH-insensitive glucose indicator protein
EP2663578A2 (en) * 2011-01-14 2013-11-20 Five Prime Therapeutics, Inc. Il-27 antagonists for treating inflammatory diseases
WO2018075740A1 (en) * 2016-10-21 2018-04-26 Merck Sharp & Dohme Corp. Treating cancer with a combination of pd-1 antagonist and an il-27 antagonist
AU2020353672A1 (en) * 2019-09-25 2022-03-31 Surface Oncology, LLC Anti-IL-27 antibodies and uses thereof
EP4192490A1 (en) 2020-08-05 2023-06-14 Synthekine, Inc. IL27Ra BINDING MOLECULES AND METHODS OF USE
CN113694201B (en) * 2021-08-26 2022-09-02 暨南大学 Compositions, methods and uses for controlling heat generation in organisms

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005079848A2 (en) * 2004-02-17 2005-09-01 Schering Corporation Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders
WO2006066088A2 (en) * 2004-12-16 2006-06-22 Genentech, Inc. Methods for treating autoimmune disorders
WO2008025031A1 (en) * 2006-08-25 2008-02-28 Zymogenetics, Inc. Treatment of graft-versus-host disease
WO2008025033A2 (en) * 2006-08-25 2008-02-28 Zymogenetics, Inc. Use of il-27 antagonists for the manufacture of a medicament for the treatment of aplastic anemia
KR20090038336A (en) * 2007-10-15 2009-04-20 가톨릭대학교 산학협력단 Pharmaceutical composition for preventing and treating autoimmune disease comprising interleukin-27 protein, il-27-fc fusion protein and mutant thereof

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
CA1338518C (en) 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
DE68925971T2 (en) 1988-09-23 1996-09-05 Cetus Oncology Corp CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF PRODUCTS
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ES2200016T3 (en) 1989-03-21 2004-03-01 Vical Incorporated EXPRESSION OF EXECUTIVE POLINUCLEOTIDIC SEQUENCES IN A VERTEBRATE.
FR2646437B1 (en) 1989-04-28 1991-08-30 Transgene Sa NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
DE69029036T2 (en) 1989-06-29 1997-05-22 Medarex Inc SPECIFIC REAGENTS FOR AIDS THERAPY
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
DE69120146T2 (en) 1990-01-12 1996-12-12 Cell Genesys Inc GENERATION OF XENOGENIC ANTIBODIES
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
DK51092D0 (en) 1991-05-24 1992-04-15 Ole Buchardt OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF
ES2206447T3 (en) 1991-06-14 2004-05-16 Genentech, Inc. HUMANIZED ANTIBODY FOR HEREGULINE.
JP3534749B2 (en) 1991-08-20 2004-06-07 アメリカ合衆国 Adenovirus-mediated gene transfer into the gastrointestinal tract
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
JPH07501451A (en) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド Multivalent antigen binding protein
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
FR2688514A1 (en) 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
JPH07507689A (en) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Specific tissue targeting methods and compositions
WO1993025698A1 (en) 1992-06-10 1993-12-23 The United States Government As Represented By The Vector particles resistant to inactivation by human serum
RU95104940A (en) 1992-07-27 1997-01-10 Хайбрайдон Method of incorporation of alkylphosphonothioate or arylphosphonothioate internucleotide linkage in oligonucleotide, method of oligonucleotide synthesis, method of gene expression inhibition, treatment method
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
ATE149570T1 (en) 1992-08-17 1997-03-15 Genentech Inc BISPECIFIC IMMUNOADHESINS
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
EP0680489A1 (en) 1993-01-21 1995-11-08 HYBRIDON, Inc. Foldback triplex-forming oligonucleotides
WO1994023697A1 (en) 1993-04-22 1994-10-27 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
ES2249761T3 (en) 1993-06-24 2006-04-01 Advec Inc. ADENOVIRUS VECTORS FOR GENE THERAPY.
CA2523216C (en) 1993-09-15 2010-11-16 Chiron Corporation Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DK0797676T3 (en) 1993-10-25 2006-04-18 Canji Inc Recombinant adenoviral vector and methods for its use
CA2176712C (en) 1993-11-16 2000-05-23 Mantripragada Sankaram Synthetic membrane vesicles with controlled release of encapsulated biologically active substances
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
DE69535669T2 (en) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. RETROVIRAL VECTORS WITH REDUCED RECOMBINATION RATE
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
AU4289496A (en) 1994-12-02 1996-06-19 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ES2304786T3 (en) 1995-04-27 2008-10-16 Amgen Fremont Inc. ANTI-IL-8 HUMAN ANTIBODIES, DERIVED FROM IMMUNIZED XENORATONES.
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
US5962674A (en) 1995-06-01 1999-10-05 Hybridon, Inc. Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages
US5614622A (en) 1995-06-01 1997-03-25 Hybridon, Inc. 5-pentenoyl moiety as a nucleoside-amino protecting group, 4-pentenoyl-protected nucleotide synthons, and related oligonucleotide syntheses
US5955599A (en) 1995-06-01 1999-09-21 Hybridon, Inc. Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages
US6140482A (en) 1995-06-01 2000-10-31 Hybridon, Inc. Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5637683A (en) 1995-07-13 1997-06-10 Cornell Research Foundation, Inc. Nucleic acid analog with amide linkage and method of making that analog
US5652356A (en) 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
DE19544393A1 (en) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistic herbicidal mixtures
ATE424463T1 (en) 1996-05-06 2009-03-15 Oxford Biomedica Ltd RECOMBINATION-INCAPABLE RETROVIRAL VECTORS
AU4089397A (en) 1996-08-26 1998-03-19 Hybridon, Inc. Improved reagents and process for synthesis of oligonucleotides containing phosphorodithioate internucleoside linkages
US5886165A (en) 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
DK1500329T3 (en) 1996-12-03 2012-07-09 Amgen Fremont Inc Human antibodies that specifically bind TNF-alpha
US5739314A (en) 1997-04-25 1998-04-14 Hybridon, Inc. Method for synthesizing 2'-O-substituted pyrimidine nucleosides
ATE531812T1 (en) 1997-12-05 2011-11-15 Scripps Research Inst HUMANIZATION OF RODENT ANTIBODIES
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
ATE375365T1 (en) 1998-04-02 2007-10-15 Genentech Inc ANTIBODIES VARIANTS AND FRAGMENTS THEREOF
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
ATE332909T1 (en) 1999-03-24 2006-08-15 Exiqon As IMPROVED SYNTHESIS FOR 2.2.1.ÖBICYCLO-NUCLEOSIDES
KR20010001577A (en) 1999-06-07 2001-01-05 윤종용 Process for Preparing Oligopeptidenucleotide Probe Using Polymeric Photoacid Generator
AU6629200A (en) 1999-08-25 2001-03-19 Philip P Garner Alpha-helical peptide nucleic acid alpha-pna
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US6455308B1 (en) 2001-08-01 2002-09-24 Isis Pharmaceuticals, Inc. Antisense modulation of serum amyloid A4 expression
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040119010A1 (en) 2002-11-01 2004-06-24 The Regents Of The University Of Colorado Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
CN104951686B (en) 2015-07-07 2020-08-04 京东方科技集团股份有限公司 Mobile terminal and method for controlling mobile terminal

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005079848A2 (en) * 2004-02-17 2005-09-01 Schering Corporation Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders
WO2006066088A2 (en) * 2004-12-16 2006-06-22 Genentech, Inc. Methods for treating autoimmune disorders
WO2008025031A1 (en) * 2006-08-25 2008-02-28 Zymogenetics, Inc. Treatment of graft-versus-host disease
WO2008025033A2 (en) * 2006-08-25 2008-02-28 Zymogenetics, Inc. Use of il-27 antagonists for the manufacture of a medicament for the treatment of aplastic anemia
KR20090038336A (en) * 2007-10-15 2009-04-20 가톨릭대학교 산학협력단 Pharmaceutical composition for preventing and treating autoimmune disease comprising interleukin-27 protein, il-27-fc fusion protein and mutant thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
GEE KATRINA ET AL: "The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders", INFLAMMATION & ALLERGY DRUG TARGETS, BENTHAM SCIENCE PUBLISHERS LNKD- DOI:10.2174/187152809787582507, vol. 8, no. 1, 1 March 2009 (2009-03-01), pages 40 - 52, XP008105853, ISSN: 1871-5281 *
HUNTER CHRISTOPHER A: "New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions", NATURE REVIEWS. IMMUNOLOGY, NATURE PUBLISHING GROUP, GB LNKD- DOI:10.1038/NRI1648, vol. 5, no. 7, 1 July 2005 (2005-07-01), pages 521 - 531, XP002455691, ISSN: 1474-1733 *
IGAWA TAKASHI ET AL: "Deficiency in EBV-induced gene 3 (EBI3) in MRL/lpr mice results in pathological alteration of autoimmune glomerulonephritis and sialadenitis.", MODERN RHEUMATOLOGY / THE JAPAN RHEUMATISM ASSOCIATION 2009 LNKD- PUBMED:18779924, vol. 19, no. 1, 2009, pages 33 - 41, XP002595469, ISSN: 1439-7595 *
SUGIYAMA N ET AL: "Amelioration of human lupus-like phenotypes in MRL/lpr mice by overexpression of interleukin 27 receptor alpha (WSX-1)", ANNALS OF THE RHEUMATIC DISEASES, vol. 67, no. 10, October 2008 (2008-10-01), pages 1461 - 1467, XP002595467, ISSN: 0003-4967 *
TAKATORI H ET AL: "New complexities in helper T cell fate determination and the implications for autoimmune diseases", MODERN RHEUMATOLOGY 2008 JP LNKD- DOI:10.1007/S10165-008-0099-Z, vol. 18, no. 6, 2008, pages 533 - 541, XP002595470 *
TERAMOTO KAE ET AL: "Microarray analysis of glomerular gene expression in murine lupus nephritis", JOURNAL OF PHARMACOLOGICAL SCIENCES, vol. 106, no. 1, January 2008 (2008-01-01), pages 56 - 67, XP002595471, ISSN: 1347-8613 *
YOSHIDA H ET AL: "Interleukin 27 signaling pathways in regulation of immune and autoimmune responses", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, EXETER, GB LNKD- DOI:10.1016/J.BIOCEL.2008.05.020, vol. 40, no. 11, 1 January 2008 (2008-01-01), pages 2379 - 2383, XP023520058, ISSN: 1357-2725, [retrieved on 20080608] *
YOSHIDA HIROKI ET AL: "Regulation of immune responses by interleukin-27.", IMMUNOLOGICAL REVIEWS DEC 2008 LNKD- PUBMED:19161428, vol. 226, December 2008 (2008-12-01), pages 234 - 247, XP002595468, ISSN: 1600-065X *
YOSHIMURA TAKERU ET AL: "Two-sided role of IL-27: Induction of Th1 differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 177, 15 October 2007 (2007-10-15), pages 5377 - 5385, XP002463417, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
US20100297127A1 (en) 2010-11-25
WO2010118243A2 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
WO2011141823A3 (en) Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
WO2010118243A3 (en) Use of il-27 antagonists to treat lupus
WO2013025997A3 (en) Brain stimulation methods for treating central sensitivity
MX355543B (en) Peptidomimetic macrocycles.
EP2569434A4 (en) Compositions and methods for treating leukemia
NZ601065A (en) Wnt antagonists and methods of treatment and screening
MX356802B (en) Biological markers for identifying patients for treatment with vegf antagonists.
WO2014138429A3 (en) Peptidomimetic macrocycles and use thereof in regulating hif1alpha
MY186099A (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
EA201200793A1 (en) TREATMENT OF GENOTYPED PATIENTS WITH DIABETES DPP-4 INHIBITORS, SUCH AS LINAGLIPTIN
WO2013033627A3 (en) Diagnosis and treatment of arthritis using epigenetics
MX2014011134A (en) Carbamate compounds and of making and using same.
MX2012010404A (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease.
MX2021001169A (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino}acetic acid, compositions, and uses thereof.
WO2010083385A3 (en) Compounds for reducing drug resistance and uses thereof
WO2012173846A3 (en) Peptidomimetic macrocycles
MX2012000034A (en) Methods for treating or preventing fatigue.
WO2015031808A3 (en) Diagnostic methods and compositions for treatment of glioblastoma
MY150600A (en) Use of opioid antagonists for treating urinary retention
TW201611843A (en) Methods of treatment with arginine deiminase
MX370417B (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases.
EA201300871A1 (en) DERIVATIVES (1,2,4) TRIAZOLO [4,3-a] CHINOXALINE AS PHOSPHODYESTERES INHIBITORS
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
MX2012013875A (en) Peripheral blood sparc antibodies and uses thereof.
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10713406

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 10713406

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE